ImmunoGen: Tremendous Value In Your Turnaround Stock

3/26/20

By BioSci Capital Partners, SeekingAlpha

Summary

  • Despite the Corona bear market, ImmunoGen is showing signs of a comeback.
  • In its latest earnings report, the company demonstrated substantial spending reductions. Hence, the net earnings came in positive.
  • On the clinical front, the Phase 3 SORAYA trail studying Mirvetuximab for ovarian cancer will enroll patients this quarter. The confirmatory Phase 3 MIRASOL study is already enrolling patients.
  • I do much more than just articles at Integrated BioSci Investing: Members get access to model portfolios, regular updates, a chat room, and more. Get started today ยป

Bull markets are born on pessimism, grown on skepticism, mature on optimism and die on euphoria. - Sir John Templeton

One of the best times for you to invest in a stock is when it tumbled far below its true worth. This usually occurs during a downturn like this corona bear market. However, you have to study the company's fundamentals meticulously. That way, you can determine if it'll be able to rebound. If it does, the profits are phenomenal for a turnaround company.

That being said, ImmunoGen (NASDAQ:IMGN) epitomizes the said phenomenon. Back in May 2019, the shares exchanged hands as low as $1.82. Notably, the depreciation is related to the FDA's deny of Mirvetuximab (Mirve) for ovarian cancer. Since its lowest peak, the stock is trading at $3.41 and thereby procured 87.3% gains. In this article, I'll feature an update on ImmunoGen and provide my expectation of its turnaround progress.

Figure 1: ImmunoGen chart (Source: StockCharts)

About The company

As usual, I'll present a brief corporate overview for new investors. If you are familiar with the firm, I recommend that you skip to the subsequent section. Operating out of Waltham, Massachusetts, ImmunoGen dedicates its efforts to the innovation and commercialization of antibody-drug conjugate ("ADC"). Specifically, the company aims to fill the unmet needs of various cancers.

In its turnaround, ImmunoGen is laser-beam focused on developing a concentrated pipeline. Aside from the crown jewel (Mirve), the company is brewing IMGN632, IMGC9326, and IMGN151.

READ FULL ARTICLE HERE